Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Sep;9(5):358-65.
doi: 10.1007/s11908-007-0056-6.

Sepsis mediators

Affiliations

Sepsis mediators

François Philippart et al. Curr Infect Dis Rep. 2007 Sep.

Abstract

During sepsis, the plasma levels of numerous inflammatory markers are enhanced. Some of these markers are the mediators responsible for the syndromes observed during sepsis as well as for organ dysfunction and eventually death. Their role has been demonstrated in experimental models that employed either transgenic and gene-targeted animals or the use of neutralizing agents. Accordingly, anaphylatoxins generated after complement system activation, factors of coagulation and fibrinolysis, proinflammatory cytokines, chemokines, proteases, lipid mediators, nitric oxide, and cell markers of stress (eg, high mobility group box-1) have been shown to contribute to the deleterious events observed during sepsis. On the other hand, the counter-regulation of the inflammatory process, which involves mediators such as anti-inflammatory cytokines and some neuromediators, can jeopardize the immune status of the host and render the patients more sensitive to nosocomial infections.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Haeffner-Cavaillon N., Cavaillon J.M., Laude M., Kazatchkine M.D. C3a(C3adesArg) induces production and release of interleukin 1 by cultured human monocytes. J Immunol. 1987;139:794–799. - PubMed
    1. Cavaillon J.M., Fitting C., Haeffner-Cavaillon N. Recombinant C5a enhances interleukin 1 and tumor necrosis factor release by lipopolysaccharide-stimulated monocytes and macrophages. Eur J Immunol. 1990;20:253–257. doi: 10.1002/eji.1830200204. - DOI - PubMed
    1. Niederbichler A.D., Hoesel L.M., Westfall M.V., et al. An essential role for complement C5a in the pathogenesis of septic cardiac dysfunction. J Exp Med. 2006;203:53–61. doi: 10.1084/jem.20051207. - DOI - PMC - PubMed
    1. Ward P.A. The dark side of C5a in sepsis. Nature Rev Immunol. 2004;4:133–142. doi: 10.1038/nri1269. - DOI - PubMed
    1. Liu D., Zhang D., Scafidi J., et al. C1 inhibitor prevents Gram-negative bacterial lipopolysaccharide-induced vascular permeability. Blood. 2005;105:2350–2355. doi: 10.1182/blood-2004-05-1963. - DOI - PubMed